|
1
|
Lavanchy D: Worldwide epidemiology of HBV
infection, disease burden, and vaccine prevention. J Clin Virol.
34(Suppl 1): S1–S3. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abdurakhmanov DT: Chronic HBV infection.
Klin Med (Mosk). 80:20–26. 2002.(In Russian).
|
|
3
|
Rapicetta M, Ferrari C and Levrero M:
Viral determinants and host immune responses in the pathogenesis of
HBV infection. J Med Virol. 67:454–457. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura I, Ochiai K and Imawari M:
Persistent infection of HBV - host-related factors and viral
factors. Nihon Rinsho. 62(Suppl 8): S112–S115. 2004.(In
Japanese).
|
|
5
|
Bertoletti A and Ferrari C: Kinetics of
the immune response during HBV and HCV infection. Hepatology.
38:4–13. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takaki A, Tatsukawa M, Koike K and
Shiratori Y: Mechanism of immune surveillance against HBV
infection. Nihon Rinsho. 62(Suppl 8): S62–S65. 2004.(In
Japanese).
|
|
7
|
Zeng R, Spolski R, Casas E, Zhu W, Levy DE
and Leonard WJ: The molecular basis of IL-21-mediated
proliferation. Blood. 109:4135–4142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Z, Yang L, Cui Y, et al: Il-21
enhances NK cell activation and cytolytic activity and induces Th17
cell differentiation in inflammatory bowel disease. Inflamm Bowel
Dis. 15:1133–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parrish-Novak J, Foster DC, Holly RD and
Clegg CH: Interleukin-21 and the IL-21 receptor: novel effectors of
NK and T cell responses. J Leukoc Biol. 72:856–863. 2002.PubMed/NCBI
|
|
10
|
Wang T, Diaz-Rosales P, Costa MM, et al:
Functional characterization of a nonmammalian IL-21: rainbow trout
Oncorhynchus mykiss IL-21 upregulates the expression of the
Th cell signature cytokines IFN-gamma, IL-10, and IL-22. J Immunol.
186:708–721. 2011.PubMed/NCBI
|
|
11
|
MacDonald TT, Bell I and Monteleone G: The
opposing roles of IL-21 and TGFβ1 in chronic inflammatory bowel
disease. Biochem Soc Trans. 39:1061–1066. 2011.
|
|
12
|
Liu L, Xu Y, Wang J and Li H: Upregulated
IL-21 and IL-21 receptor expression is involved in experimental
autoimmune uveitis (EAU). Mol Vis. 15:2938–2944. 2009.PubMed/NCBI
|
|
13
|
Bubier JA, Sproule TJ, Foreman O, et al: A
critical role for IL-21 receptor signaling in the pathogenesis of
systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci
USA. 106:1518–1523. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu R, Wu Q, Su D, et al: A regulatory
effect of IL-21 on T follicular helper-like cell and B cell in
rheumatoid arthritis. Arthritis Res Ther. 14:R2552012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshizaki A, Miyagaki T, DiLillo DJ, et
al: Regulatory B cells control T-cell autoimmunity through
IL-21-dependent cognate interactions. Nature. 491:264–268. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Habib T, Senadheera S, Weinberg K and
Kaushansky K: The common gamma chain (gamma c) is a required
signaling component of the IL-21 receptor and supports
IL-21-induced cell proliferation via JAK3. Biochemistry.
41:8725–8731. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Totero D, Meazza R, Capaia M, et al:
The opposite effects of IL-15 and IL-21 on CLL B cells correlate
with differential activation of the JAK/STAT and ERK1/2 pathways.
Blood. 111:517–524. 2008.PubMed/NCBI
|
|
18
|
Asao H, Okuyama C, Kumaki S, et al:
Cutting edge: the common gamma-chain is an indispensable subunit of
the IL-21 receptor complex. J Immunol. 167:1–5. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ettinger R, Kuchen S and Lipsky PE: The
role of IL-21 in regulating B-cell function in health and disease.
Immunol Rev. 223:60–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson LD and Jameson SC: Immunology. A
chronic need for IL-21. Science. 324:1525–1526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deenick EK and Tangye SG: Autoimmunity:
IL-21: a new player in Th17-cell differentiation. Immunol Cell
Biol. 85:503–505. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barker BR, Gladstone MN, Gillard GO, Panas
MW and Letvin NL: Critical role for IL-21 in both primary and
memory anti-viral CD8+ T-cell responses. Eur J Immunol.
40:3085–3096. 2010.PubMed/NCBI
|
|
23
|
Nurieva R, Yang XO, Martinez G, et al:
Essential autocrine regulation by IL-21 in the generation of
inflammatory T cells. Nature. 448:480–483. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McGavern DB: A little ‘help’ from IL-21
during persistent viral infection. J Mol Cell Biol. 2:8–10.
2010.
|
|
25
|
Zhao CC, Xue J, Cong Z, et al: Circulating
IL-21 levels increase during early simian-human immunodeficiency
virus infection in macaques. Arch Virol. 158:853–858. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pallikkuth S, Parmigiani A and Pahwa S:
Role of IL-21 and IL-21 receptor on B cells in HIV infection. Crit
Rev Immunol. 32:173–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Papatriantafyllou M: Antiviral immunity:
IL-21 comes with age. Nat Rev Immunol. 11:236–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iannello A, Boulassel MR, Samarani S, et
al: Dynamics and consequences of IL-21 production in HIV-infected
individuals: a longitudinal and cross-sectional study. J Immunol.
184:114–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iannello A, Samarani S and Ahmad A:
Comment on ‘HIV-specific IL-21 producing CD4+ T cells are induced
in acute and chronic progressive HIV infection and are associated
with relative viral control’. J Immunol. 185:56752010.
|
|
30
|
Elsaesser H, Sauer K and Brooks DG: IL-21
is required to control chronic viral infection. Science.
324:1569–1572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Green KJ, Rowbottom DG and Mackinnon LT:
Exercise and T-lymphocyte function: a comparison of proliferation
in PBMC and NK cell-depleted PBMC culture. J Appl Physiol (1985).
92:2390–2395. 2002.PubMed/NCBI
|
|
32
|
Cho SH, Stanciu LA, Begishivili T, Bates
PJ, Holgate ST and Johnston SL: Peripheral blood CD4+ and CD8+ T
cell type 1 and type 2 cytokine production in atopic asthmatic and
normal subjects. Clin Exp Allergy. 32:427–433. 2002.
|
|
33
|
Gauduin MC, Kaur A, Ahmad S, Yilma T,
Lifson JD and Johnson RP: Optimization of intracellular cytokine
staining for the quantitation of antigen-specific CD4+ T cell
responses in rhesus macaques. J Immunol Methods. 288:61–79.
2004.
|
|
34
|
Garba ML and Frelinger JA: Intracellular
cytokine staining for TGF-beta. J Immunol Methods. 258:193–198.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Paunio M, Heinonen OP, Virtanen M,
Leinikki P, Patja A and Peltola H: Measles history and atopic
diseases: a population-based cross-sectional study. JAMA.
283:343–346. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goeser T and Töx U: Therapy of hepatitis B
and C. Problem situations in chronic HBV and HCV infection. Praxis
(Bern 1994). 91:983–990. 2002.(In German).
|
|
37
|
Kuo A and Gish R: Chronic hepatitis B
infection. Clin Liver Dis. 16:347–369. 2012. View Article : Google Scholar
|
|
38
|
Ma SW, Huang X, Li YY, et al: High serum
IL-21 levels after 12 weeks of antiviral therapy predict HBeAg
seroconversion in chronic hepatitis B. J Hepatol. 56:775–781. 2012.
View Article : Google Scholar
|
|
39
|
Grimm D, Heeg M and Thimme R: Hepatitis B
virus: from immunobiology to immunotherapy. Clin Sci (Lond).
124:77–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Michailidis E, Kirby KA, Hachiya A, et al:
Antiviral therapies: focus on hepatitis B reverse transcriptase.
Int J Biochem Cell Biol. 44:1060–1071. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hann HW: Telbivudine: an effective
anti-HBV drug for chronic hepatitis B patients with early
on-treatment responses. Expert Opin Pharmacother. 11:2243–2249.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li X, Wang Y, Han D, et al: Correlation of
hepatitis B surface antigen level with response to telbivudine in
naive patients with chronic hepatitis B. Hepatol Res. Mar
4–2013.(Epub ahead of print).
|
|
43
|
Sarin SK, Kumar A, Almeida JA, et al:
Acute-on-chronic liver failure: consensus recommendations of the
Asian Pacific Association for the study of the liver (APASL).
Hepatol Int. 3:269–282. 2009. View Article : Google Scholar
|
|
44
|
Du WB, Li LJ, Huang JR, et al: Effects of
artificial liver support system on patients with acute or chronic
liver failure. Transplant Proc. 37:4359–4364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ren X, Xu Z, Liu Y, et al: Hepatitis B
virus genotype and basal core promoter/precore mutations are
associated with hepatitis B-related acute-on-chronic liver failure
without pre-existing liver cirrhosis. J Viral Hepat. 17:887–895.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang Z, Zou ZS, Fu JL, et al: Severe
dendritic cell perturbation is actively involved in the
pathogenesis of acute-on-chronic hepatitis B liver failure. J
Hepatol. 49:396–406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zou Y, Chen T, Han M, et al: Increased
killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand
contributes to hepatocyte necrosis in virus-induced liver failure.
J Immunol. 184:466–475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu D, Fu J, Jin L, et al: Circulating and
liver resident CD4+CD25+ regulatory T cells actively influence the
antiviral immune response and disease progression in patients with
hepatitis B. J Immunol. 177:739–747. 2006.
|
|
49
|
Zhang JY, Zhang Z, Lin F, et al:
Interleukin-17-producing CD4(+) T cells increase with severity of
liver damage in patients with chronic hepatitis B. Hepatology.
51:81–91. 2010.
|
|
50
|
Hu X, Ma S, Huang X, et al: Interleukin-21
is upregulated in hepatitis B-related acute-on-chronic liver
failure and associated with severity of liver disease. J Viral
Hepat. 18:458–467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hashmi MH and Van Veldhuizen PJ:
Interleukin-21: updated review of Phase I and II clinical trials in
metastatic renal cell carcinoma, metastatic melanoma and
relapsed/refractory indolent non-Hodgkin’s lymphoma. Expert Opin
Biol Ther. 10:807–817. 2010.PubMed/NCBI
|
